Headlines about Galapagos (NASDAQ:GLPG) have been trending somewhat positive recently, according to Accern. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Galapagos earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.7159929660879 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Galapagos (GLPG) traded up $3.94 during midday trading on Friday, hitting $108.38. 107,808 shares of the company’s stock were exchanged, compared to its average volume of 73,656. The stock has a market capitalization of $5,320.00, a PE ratio of -106.90 and a beta of 0.75. Galapagos has a fifty-two week low of $63.69 and a fifty-two week high of $108.47.
Several equities research analysts have weighed in on GLPG shares. Zacks Investment Research downgraded shares of Galapagos from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. Stifel Nicolaus restated a “buy” rating and issued a $120.00 target price on shares of Galapagos in a research note on Sunday, October 29th. BTIG Research restated a “buy” rating and issued a $118.00 target price on shares of Galapagos in a research note on Monday, November 20th. Morgan Stanley reaffirmed an “overweight” rating and issued a $123.00 price target (up previously from $92.00) on shares of Galapagos in a report on Friday, October 6th. Finally, BidaskClub cut shares of Galapagos from a “sell” rating to a “strong sell” rating in a report on Saturday, December 2nd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $111.00.
Galapagos Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.